Developer docs
API playgroundTry for free, no card

Search company profiles

Blackrock Microsystems

Full company profile

uuid000221x

Namestring
Blackrock Microsystems
Legal namestring
Blackrock Microsystems, Inc.
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Blackrock Microsystems, Inc., operating as Blackrock Neurotech, is a privately held neurotechnology company headquartered in Salt Lake City, USA, founded in 2005. The company has developed a brain-computer interface (BCI) platform that decodes neural signals in real time, allowing patients with paralysis and other neurological disorders to control external devices through thought alone. Documented capabilities include typing at up to 90 characters per minute, decoding up to 62 words per minute from neural signals, and operating robotic arms, email clients, and creative software without physical input. The platform is backed by 19+ years of human studies, 30,000+ days of implant research, and 2,000+ peer-reviewed publications, giving it one of the deepest clinical evidence bases in the BCI field.

The company's revenue model operates along two customer tracks. The first is direct sales of neurotechnology devices (electrode arrays, recording systems, and supporting hardware/software) to research institutions; the company states it has equipped more than 1,000 laboratories at world-renowned universities and research centers worldwide. The second is the BCI Pioneer program, a direct-to-patient clinical engagement for individuals with paralysis and neurological disorders, supported by clinical partners. Pricing is not publicly disclosed, but the model resembles a high-value, low-volume medical device sale with multi-year capital and consumable streams. Marketing is conducted through owned digital channels (Twitter/X, LinkedIn, YouTube, Instagram, Facebook, newsletter, corporate website), with no evidence of third-party distribution or marketplace channels.

In May 2024, Blackrock filed a Form D with the SEC for an exempt securities offering of approximately $12.37 million involving multiple related persons and executive officers, indicating an active capital-raising posture. The company maintains an operational website (copyright 2026) and ongoing news output. The addressable market is supported by a third-party projection of a $0.95 billion BCI market by 2035. Revenue magnitude, profitability, unit pricing, and detailed customer economics are not disclosed in the available data, which limits financial diligence.

Short descriptiontext

Blackrock Microsystems (operating as Blackrock Neurotech) is a private Salt Lake City-based neurotechnology company that builds brain-computer interface systems enabling paralyzed patients to control devices via thought, and sells its BCI platform to over 1,000 research institutions globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSalt Lake City, United States
HQ citystring
Salt Lake City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
brain-computer interface, neurotechnology devices, neural signal processing, neuroprosthetic systems, neural recording platforms
Industry2 codes
PRIMARYHDAHABAC
Compute & Acceleration ICs (CPU/GPU/AI/FPGA/ASIC)
SECONDARYHDAHAJAB
Application Processors & Microprocessors (MPUs/CPUs)
NAICS code2 codes
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
  • Semiconductor and Other Electronic Component Manufacturing3344
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Semiconductors & Related Devices3674
Product category
Neurotechnology Devices
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Blackrock Microsystems (operating as Blackrock Neurotech) develops and manufactures brain-computer interface (BCI) neurotechnology platforms and devices. The company sells these neurotechnology devices to research institutions worldwide (equipping over 1,000 labs) and operates a BCI Pioneer program that enables patients with paralysis and neurological disorders to control external devices — including typing at up to 90 characters per minute and decoding up to 62 words per minute — through thought alone.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Typing at up to 90 characters per minute using thought
+2 more records
Product overview1 text field

Blackrock Neurotech offers a neurotechnology platform designed to improve patients' lives through brain-computer interface technology. The platform has enabled BCI Pioneers to perform daily activities such as eating, drinking, sending emails, and operating robotic arms by thinking. The company provides technology for research institutions (offering devices to over 1000 labs from world-renowned institutions) and for patients and clinicians. The platform supports capabilities including typing at up to 90 characters per minute and decoding up to 62 words per minute from thought.

Product and service3 records
1Neurotechnology Platform
CategoryNeurotechnology / Brain-Computer Interface
2Research Neurotechnology Devices
CategoryNeurotechnology / Research Equipment
3BCI Pioneer Patient Program
CategoryNeurotechnology / Clinical Application
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Closest direct competitor developing implanted BCI devices for paralysis and communication; competes head-to-head with Blackrock in human BCI implants, though backed by significantly larger capital.

TypeDirect peer
Description

Developer of a high-bandwidth cortical interface for paralyzed patients; competes in implanted BCI with overlapping neural decoding and motor-restoration use cases.

TypeDirect peer
Description

Commercial-stage neurotechnology company with the RNS System for responsive neurostimulation in epilepsy; overlaps as an implanted brain-interface device company targeting neurological disorders.

TypeEmerging player
Description

Consumer- and research-grade EEG headset maker with overlap in the research-institution segment that Blackrock serves, though operating at the non-invasive, lower-bandwidth end of the market.

TypeEmerging player
Description

Non-invasive BCI and neuroimaging company using optical/MEG approaches; competes for the broader brain-computer interface opportunity, though with non-implanted technology.

TypeDirect peer
Description

Implanted BCI company (Stentrode) targeting paralysis patients with a less-invasive vascular delivery approach; competes for the same clinical patient population as Blackrock.

TypeBroad incumbent
Description

Diversified medical device incumbent with neuromodulation products; comparable in adjacent neurotech commercialization pathways and hospital-channel reach.

TypeBroad incumbent
Description

Medical device major with a neuromodulation division (formerly St. Jude) covering spinal cord and deep brain stimulation; comparable as a scaled channel for neuro-therapeutic devices.

TypeBroad incumbent
Description

Large incumbent medical device company with deep-brain stimulation, neuromodulation, and neurosurgery franchises; overlaps with Blackrock in neurological therapeutic-device markets.

TypeDirect peer
Description

Fabless neurotechnology company building high-data-rate brain-computer interfaces; competes in the implanted neural recording and decoding category.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Blackrock Microsystems

Neurotechnology Devicesblackrockmicro.com

Blackrock Microsystems (operating as Blackrock Neurotech) is a private Salt Lake City-based neurotechnology company that builds brain-computer interface systems enabling paralyzed patients to control devices via thought, and sells its BCI platform to over 1,000 research institutions globally.

What Blackrock Microsystems does

Blackrock Microsystems, Inc., operating as Blackrock Neurotech, is a privately held neurotechnology company headquartered in Salt Lake City, USA, founded in 2005. The company has developed a brain-computer interface (BCI) platform that decodes neural signals in real time, allowing patients with paralysis and other neurological disorders to control external devices through thought alone. Documented capabilities include typing at up to 90 characters per minute, decoding up to 62 words per minute from neural signals, and operating robotic arms, email clients, and creative software without physical input. The platform is backed by 19+ years of human studies, 30,000+ days of implant research, and 2,000+ peer-reviewed publications, giving it one of the deepest clinical evidence bases in the BCI field.

The company's revenue model operates along two customer tracks. The first is direct sales of neurotechnology devices (electrode arrays, recording systems, and supporting hardware/software) to research institutions; the company states it has equipped more than 1,000 laboratories at world-renowned universities and research centers worldwide. The second is the BCI Pioneer program, a direct-to-patient clinical engagement for individuals with paralysis and neurological disorders, supported by clinical partners. Pricing is not publicly disclosed, but the model resembles a high-value, low-volume medical device sale with multi-year capital and consumable streams. Marketing is conducted through owned digital channels (Twitter/X, LinkedIn, YouTube, Instagram, Facebook, newsletter, corporate website), with no evidence of third-party distribution or marketplace channels.

In May 2024, Blackrock filed a Form D with the SEC for an exempt securities offering of approximately $12.37 million involving multiple related persons and executive officers, indicating an active capital-raising posture. The company maintains an operational website (copyright 2026) and ongoing news output. The addressable market is supported by a third-party projection of a $0.95 billion BCI market by 2035. Revenue magnitude, profitability, unit pricing, and detailed customer economics are not disclosed in the available data, which limits financial diligence.

Blackrock Microsystems firmographics

Firmographics
Name
Blackrock Microsystems
Legal name
Blackrock Microsystems, Inc.
Website
https://blackrockmicro.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
101–250 employees
Short description
Blackrock Microsystems (operating as Blackrock Neurotech) is a private Salt Lake City-based neurotechnology company that builds brain-computer interface systems enabling paralyzed patients to control devices via thought, and sells its BCI platform to over 1,000 research institutions globally.
Ownership category
akta.pro rank

Blackrock Microsystems industry classification

Industry
Product category
Neurotechnology Devices
NAICS
Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Semiconductor and Other Electronic Component Manufacturing (3344)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Semiconductors & Related Devices (3674)
akta.pro industry
PRIMARYHDAHABAC
Compute & Acceleration ICs (CPU/GPU/AI/FPGA/ASIC)
SECONDARYHDAHAJAB
Application Processors & Microprocessors (MPUs/CPUs)

Keywords

  • Brain-computer interface
  • Neurotechnology devices
  • Neural signal processing
  • Neuroprosthetic systems
  • Neural recording platforms

Where Blackrock Microsystems is headquartered

Location

Headquarters

HQ city
Salt Lake City
HQ country
United States
HQ region
North America

Markets served

Blackrock Microsystems business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Distribution channels2 records

Marketing channels3 records

Blackrock Microsystems product offering

Product offering

Core offering

Blackrock Microsystems (operating as Blackrock Neurotech) develops and manufactures brain-computer interface (BCI) neurotechnology platforms and devices. The company sells these neurotechnology devices to research institutions worldwide (equipping over 1,000 labs) and operates a BCI Pioneer program that enables patients with paralysis and neurological disorders to control external devices — including typing at up to 90 characters per minute and decoding up to 62 words per minute — through thought alone.

Product overview

Blackrock Neurotech offers a neurotechnology platform designed to improve patients' lives through brain-computer interface technology. The platform has enabled BCI Pioneers to perform daily activities such as eating, drinking, sending emails, and operating robotic arms by thinking. The company provides technology for research institutions (offering devices to over 1000 labs from world-renowned institutions) and for patients and clinicians. The platform supports capabilities including typing at up to 90 characters per minute and decoding up to 62 words per minute from thought.

Differentiator

Problem solved

Functional benefit

Products and services

  • Neurotechnology Platform
  • Research Neurotechnology Devices
  • BCI Pioneer Patient Program

Quantifiable outcome

  • Typing at up to 90 characters per minute using thought
  • +2 more outcomes

Companies that use Blackrock Microsystems

Customer profile

Segments2 records

Ideal customer profiles2 records

Blackrock Microsystems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Blackrock Microsystems partnerships and signals

Strategic signal

Scale indicators6 records

Expansion highlights5 records

Blackrock Microsystems competitors and assessment

Company assessment

Direct peers

  • Neuralink: Closest direct competitor developing implanted BCI devices for paralysis and communication; competes head-to-head with Blackrock in human BCI implants, though backed by significantly larger capital.
  • Precision Neuroscience: Developer of a high-bandwidth cortical interface for paralyzed patients; competes in implanted BCI with overlapping neural decoding and motor-restoration use cases.
  • NeuroPace: Commercial-stage neurotechnology company with the RNS System for responsive neurostimulation in epilepsy; overlaps as an implanted brain-interface device company targeting neurological disorders.
  • Synchron: Implanted BCI company (Stentrode) targeting paralysis patients with a less-invasive vascular delivery approach; competes for the same clinical patient population as Blackrock.
  • Paradromics: Fabless neurotechnology company building high-data-rate brain-computer interfaces; competes in the implanted neural recording and decoding category.

Emerging players

  • Emotiv: Consumer- and research-grade EEG headset maker with overlap in the research-institution segment that Blackrock serves, though operating at the non-invasive, lower-bandwidth end of the market.
  • Kernel: Non-invasive BCI and neuroimaging company using optical/MEG approaches; competes for the broader brain-computer interface opportunity, though with non-implanted technology.

Broad incumbents

  • Boston Scientific: Diversified medical device incumbent with neuromodulation products; comparable in adjacent neurotech commercialization pathways and hospital-channel reach.
  • Abbott: Medical device major with a neuromodulation division (formerly St. Jude) covering spinal cord and deep brain stimulation; comparable as a scaled channel for neuro-therapeutic devices.
  • Medtronic: Large incumbent medical device company with deep-brain stimulation, neuromodulation, and neurosurgery franchises; overlaps with Blackrock in neurological therapeutic-device markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights5 records

Customer concentration

Blackrock Microsystems social profiles

Digital presence

Blackrock Microsystems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Blackrock Microsystems leadership team

Management profile

Number of profiles

Profiles7 records

Blackrock Microsystems funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Blackrock Microsystems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blackrock Microsystems

What does Blackrock Microsystems do?

Blackrock Microsystems (operating as Blackrock Neurotech) develops and manufactures brain-computer interface (BCI) neurotechnology platforms and devices. The company sells these neurotechnology devices to research institutions worldwide (equipping over 1,000 labs) and operates a BCI Pioneer program that enables patients with paralysis and neurological disorders to control external devices — including typing at up to 90 characters per minute and decoding up to 62 words per minute — through thought alone.

Is Blackrock Microsystems a public or private company?

Blackrock Microsystems is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Blackrock Microsystems founded?

Blackrock Microsystems was founded in 2005. It employs 101 to 250 people.

Where is Blackrock Microsystems based?

Blackrock Microsystems is headquartered in Salt Lake City, United States, in the North America region.

Who are Blackrock Microsystems's main competitors?

Direct peers on record are Neuralink, Precision Neuroscience, NeuroPace, Synchron and Paradromics. Emerging players are Emotiv and Kernel. Broad incumbents are Boston Scientific, Abbott and Medtronic.

Does Blackrock Microsystems have an API?

No public API is recorded for Blackrock Microsystems.

What industry is Blackrock Microsystems in?

Blackrock Microsystems's product category is Neurotechnology Devices. Its primary akta.pro industry code is HDAHABAC, Compute & Acceleration ICs (CPU/GPU/AI/FPGA/ASIC), with a secondary code of HDAHAJAB, Application Processors & Microprocessors (MPUs/CPUs). Its NAICS code is 33451 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LinkedInNeural Signal Acquisition System Market Leaders, AI Trends & Size 2026-2033Market Size And Trends has published a research report projecting the global neural signal acquisition system market to grow from USD 1.2 billion in 2024 to USD 3.08 billion by 2033, at a CAGR of 12.5%. The report identifies key growth drivers such as technological advancements in AI and wireless systems, rising prevalence of neurological disorders, and increasing demand for non-invasive monitoring solutions. Major industry players including Medtronic PLC, Blackrock Microsystems, and Ripple Neuro are highlighted as active participants shaping this expanding sector.Data Insights MarketNeural Signal Acquisition System Soars to XXX million, witnessing a CAGR of XX during the forecast period 2025-2033The global Neural Signal Acquisition System market is projected to reach approximately $3,500 million by 2025, growing at a CAGR of 12.5% through 2033, driven by rising neurological disorder prevalence and BCI adoption. Key industry players including Medtronic, Nihon Kohden, Blackrock Microsystems, and Natus are actively innovating with AI integration, miniaturization, and new product launches to capture market share. North America remains the dominant region due to high healthcare expenditure and robust neuroscience research funding.BlackrockneurotechBlackrock NeurotechThe article outlines the historical development of brain-computer interface technology, specifically highlighting Blackrock Microsystems' acquisition of Cyberkinetics and its role in providing hardware for various clinical trials. It details milestones achieved by research institutions like Brown University, Johns Hopkins University, and UCSF using Blackrock's Utah Array and NeuroPort systems to enable motor control, sensory feedback, and speech decoding. These developments demonstrate the progression of neuroprosthetics from animal studies to human applications for restoring movement and sensation.SecSEC FORM DBlackrock Microsystems, Inc. filed a Form D with the U.S. Securities and Exchange Commission for an exempt securities offering under Rule 506(b). The company reported total offering and sales amounts of $12,368,642 USD, with the first sale occurring on April 29, 2024. The filing indicates that equity securities were offered to 31 investors.PR NewswireJet Lag Soon To Be Obsolete? Blackrock Microsystems Joins Team At Northwestern University To Develop "Living Pharmacy" Using Device To Control Circadian ClockBlackrock Microsystems has partnered with Northwestern University and Rice University researchers to develop a wireless, fully implantable device aimed at resetting the body's circadian clock to alleviate jet lag. Funded by DARPA under its ADAPTER program, the project utilizes synthetic biology and bioelectronics to create a "living pharmacy" that releases precise doses of peptides in response to light exposure. This technology targets military personnel and first responders initially, with potential future applications for general patients suffering from sleep cycle disruptions.GlobeNewswireClearPoint Neuro, Inc. Announces Multi-Product Joint Development & Option Agreement with Blackrock MicrosystemsClearPoint Neuro announced a multi-product joint development and option agreement with Blackrock Microsystems. The partnership targets a combined addressable market of over $100 million, with initial product launches in 2023 starting with the Microelectric Recording platform.Business Wire BlogBlackrock Microsystems Licenses Wyss Center’s Real-time Neural Signal Processing PlatformThe Wyss Center granted Blackrock Microsystems a worldwide license to commercialize its NeuroKey neural signal processing platform for research and clinical brain-computer interface applications. The platform is optimized for implantable, high-channel count BCIs and aims to accelerate clinical deployment. The partnership is intended to be the first of many joint neurotechnology developments.